Journal
ENDOCRINE REVIEWS
Volume 43, Issue 4, Pages 678-719Publisher
ENDOCRINE SOC
DOI: 10.1210/endrev/bnab039
Keywords
uterine fibroids; developmental origin; genetic instability; reprogramming; epigenetics pathways; novel treatment; future directions
Categories
Funding
- National Institutes of Health [RO1 ES028615, RO1 HD094378, U54 MD007602, RO1 087417, RO1 HD094380, HD106285]
Ask authors/readers for more resources
This article comprehensively summarizes recent research progress on uterine fibroids, including risk factors, development origin, pathogenetic mechanisms, and treatment options. Deeper insights into tumor etiology and the complexity of uterine fibroids can contribute to the progress of newer targeted therapies.
Uterine fibroids are benign monoclonal neoplasms of the myometrium, representing the most common tumors in women worldwide. To date, no long-term or noninvasive treatment option exists for hormone-dependent uterine fibroids, due to the limited knowledge about the molecular mechanisms underlying the initiation and development of uterine fibroids. This paper comprehensively summarizes the recent research advances on uterine fibroids, focusing on risk factors, development origin, pathogenetic mechanisms, and treatment options. Additionally, we describe the current treatment interventions for uterine fibroids. Finally, future perspectives on uterine fibroids studies are summarized. Deeper mechanistic insights into tumor etiology and the complexity of uterine fibroids can contribute to the progress of newer targeted therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available